Introduction

Thyroid gland is an endocrine gland at the anterior of trachea between cricoid cartilage and suprasternal notch (1). This gland produces 2 important hormones namely thyroxine (T4) and triiodothyronine (T3) that exert their effects through the nuclear receptors. They play a critical role in cell differentiation during growth and development. They also maintain metabolic homeostasis in body (1). Thyroid disorders are often due to autoimmune processes that result in the increase (hyperthyroidism) or decrease of thyroid hormones (hypothyroidism) (1). The average annual incidence of autoimmune hypothyroidism is 4 cases per 1000 females and 1 case per 1000 males (1). Since autoimmune reactions reduce thyroid functions gradually, the first stages of hypothyroidism are compensated by an increase in thyroid-stimulating hormone (TSH), which maintains T4 in the normal range (2). This level is mostly observed in the initial stages of Hashimoto's disease called subclinical hypothyroidism (SCH). Patients at this stage have no symptoms or the symptoms are very mild. When the SCH is associated with antibodies against thyroid peroxidase (TPO), annual risk of developing overt hypothyroidism is about 4% (1,2).

Hyperlipidemia is one of the components of metabolic syndrome. In some studies, metabolic syndrome and its components (dyslipidemia) are responsible for 25%of the new onset cardiovascular disease (CVD) (3).Thyroid hormones have an important regulatory effect on glucose and lipid metabolism, and blood pressure control. Increasing in total cholesterol and low-density lipoprotein (LDL) in hypothyroidism might be due to several changes in the synthesis, metabolism, and fat mobilization (3). Thyroid hormones increase 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-COA) reductase activity in the liver and, thus, reduce cholesterol. In addition, thyroid hormones increase LDL receptors on fibroblasts, liver, and other tissue, and they increase absorption of cholesterol from the intestine. These hormones also alter levels of high-density lipoprotein (HDL) cholesterol and hepatic lipase activity, and affect the excretion of cholesterol from the intestine by bile acids (3). While the relationship between subclinical hypothyroidism and an increased risk of cardiovascular disease caused by atherosclerosis is shown in some studies, it is not confirmed in the other studies (3, 4). Although the effects of subclinical hypothyroidism on serum lipids are unclear, it is likely that the changes that occur in clinical hypothyroidism, exist in subclinical cases as well, but might be much less severe. Due to the role of dyslipidemia as an important risk factor of atherosclerosis, which may appear in subclinical hypothyroidism, the current study aimed at assessing the prevalence of dyslipidemia in patients with subclinical hypothyroidism, in comparison with healthy people in Hamadan, Iran.

Methods

The current cross sectional study was performed at Endocrinology Clinic of Besat Hospital in Hamadan, Iran, in 2013; 53 patients with subclinical hypothyroidism (10 mU/L > TSH >4.2 mU/L) and normal T4 (0.8 to 2.8 ng/dL), measured twice with one month interval without clinical symptoms, were selected. Also, 53 euthyroid participants with normal levels of TSH, ranged from0.5 to 4.2 mU/L were enrolled into the study as the control group. The age range of the cases was 18 to 60 years. The control group was matched with the patient group in terms of gender, age, and body mass index (BMI). For any patient with elevated TSH, the following causes were considered: Use of dopaminergic drugs, amiodarone, lithium, drugs containing iodine, circadian TSH secretion (TSH level decreases in the morning and increases in the evening), euthyroid outliers (25% of healthy people with TSH higher than normal range), and sick euthyroid syndrome. Also, patients with primary and secondary risk factors for hyperlipidemia such as history of familial hyperlipidemia, obesity, diabetes, kidney disease, and steroid users were excluded from the study. Therefore, after taking a full medical history of acute recent illnesses and previous backgrounds, patients were enrolled into the study. All thyroid panel tests were performed based on enzyme-linked fluorescent assay (ELFA) by Vitek immunodiagnostic assay system (VIDAS). For ethical purpose, each patient signed the letter of informed consent. The following procedures were in accordance with the ethical standards of the institutional or regional responsible committee on human experimentation and those of the Helsinki Declaration of 1975, as revised in 1983.

A total of 10 mL fasting venous blood samples were taken from each case in early morning to measure lipid profiles, including triglyceride (TG), HDL, LDL,, and total cholesterol (TCHOL). Dyslipidemia in Besat Hospital laboratory (according to the Harrison principles of internal medicine (1) is defined as TG >200 mg/dL, TCHOL >200 mg/dL, LDL >100 mg/dL, HDL t test and one-sample t test were used. All comparisons were based on the presence of a significant correlation with P-values

Results
In the current study, the age range of all the 53 cases with SCH, and the 53 cases as the control group was from 18 to 60 years. Among them, females were 57% and males were 49% in both groups. Table 1 shows the distribution of demographic characteristics among the study cases.

Tables 1. Demographical Characteristics of the Study Cases

BMI, body mass index

In females, the TCHOL levels of the patients group were higher than those of the control group in all age groups, but it was significant only in the age group of 40 to 50 years (P-value =0.03). The results were the same in males (P-value =0.01).

There was significant correlation between SCH and decreased level of HDL in females regardless of age groups (P-value =0.001). Also,the results of the study showed a significant correlation between increased level of LDL and SCH in all age groups of females, except the group 30 to 40 years. In males, there was no significant correlation between SCH and decreased level of HDL, or increased level of LDL in all age groups. No significant correlation between increased level of TG and SCH was observed in the 2 genders. In overall, there was significant correlation between SCH and decreased HDL level (P-value = 0.04) and also increased LDL level (P-value =0.001).

Regardless of age groups and gender, there were no significant correlations between SCH and increased levels of TG and TCHOL (P-value <0.05). The prevalence of dyslipidemia and SCH was significant in females (P-value =0.009), but not in males (P-value =0.02). Totally, there was a significant correlation between the prevalence of dyslipidemia and SCH regardless of gender (P-value =0.04). Table 2 shows the correlation between SCH and lipid profiles based in age groups and gender in summary.

F:Female; M:Male *The significant relations have bolded frame